September 8, 2011
Bernstein Liebhard LLP is investigating whether the Board of Directors of Caliper Life Sciences, Inc. (“Caliper” or the “Company”) (NASDAQ: CALP) breached its fiduciary duty to its shareholders in agreeing to sell Caliper to PerkinElmer, Inc.
Under the terms of the agreement, Caliper shareholders will receive $10.50 in cash for each share they own. The investigation is focused on the potential unfairness of the price to Caliper shareholders and the process by which the Caliper Board of Directors considered and approved the transaction.
If you are interested in discussing your rights as a Caliper shareholder and/or have information relating to the matter, please contact U. Seth Ottensoser at (877) 779-1414 or Ottensoser@bernlieb.com.
Bernstein Liebhard has pursued hundreds of securities, consumer, and antitrust cases and recovered almost $3 billion for its
clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last eight years.
